Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Sandler

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
International Journal of Radiation Oncology, Biology, Physics|January 28, 2020
VA-Radiation Oncology Quality Surveillance ProgramMichael Hagan, Rishabh Kapoor, Jeff Michalski, et al.
International Journal of Radiation Oncology, Biology, Physics|April 10, 2012
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlasHiram A Gay, H Joseph Barthold, Elizabeth O'Meara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
The Journal of Urology|September 11, 2019
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public WorkshopChana Weinstock, Daniel Suzman, Paul Kluetz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 19, 2007
Prostate cancer. Clinical practice guidelines in oncologyJames Mohler, Richard J Babaian, Robert R Bahnson, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
Practical Radiation Oncology|June 11, 2022
Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Quality Measures InitiativeJohn Park, Lindsay L Puckett, Evangelia Katsoulakis, et al.
Virchows Archiv : an International Journal of Pathology|October 16, 2014
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologistRodolfo Montironi, Elizabeth H Hammond, Daniel W Lin, et al.
Pathology|December 5, 2014
Active surveillance for prostate cancer: the role of the pathologistBrett Delahunt, Elizabeth Hammond, Lars Egevad, et al.
The Lancet. Oncology|March 4, 2021
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysisLaila A Gharzai, Ralph Jiang, David Wallington, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
International Journal of Radiation Oncology, Biology, Physics|January 28, 2020
VA-Radiation Oncology Quality Surveillance ProgramMichael Hagan, Rishabh Kapoor, Jeff Michalski, et al.
International Journal of Radiation Oncology, Biology, Physics|April 10, 2012
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlasHiram A Gay, H Joseph Barthold, Elizabeth O'Meara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
The Journal of Urology|September 11, 2019
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public WorkshopChana Weinstock, Daniel Suzman, Paul Kluetz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 19, 2007
Prostate cancer. Clinical practice guidelines in oncologyJames Mohler, Richard J Babaian, Robert R Bahnson, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
Practical Radiation Oncology|June 11, 2022
Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Quality Measures InitiativeJohn Park, Lindsay L Puckett, Evangelia Katsoulakis, et al.
Virchows Archiv : an International Journal of Pathology|October 16, 2014
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologistRodolfo Montironi, Elizabeth H Hammond, Daniel W Lin, et al.
Pathology|December 5, 2014
Active surveillance for prostate cancer: the role of the pathologistBrett Delahunt, Elizabeth Hammond, Lars Egevad, et al.
The Lancet. Oncology|March 4, 2021
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysisLaila A Gharzai, Ralph Jiang, David Wallington, et al.
Pageof 12